Literature DB >> 11743655

Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells.

Giuliana Gobbi1, Luca Sangiorgi, Luca Lenzi, Raffaella Casadei, Silvia Canaider, Pierluigi Strippoli, Enrico Lucarelli, Ilaria Ghedini, Davide Donati, Nicola Fabbri, Jorg Warzecha, Choh Yeoung, Lee J Helman, Piero Picci, Paolo Carinci.   

Abstract

Members of the bone morphogenetic protein (BMP) family and their receptors (BMPRs and activin receptors-ActRs) promote the development of bones with a fine regulation of their expression. Mutations in BMPs or BMPRs cause several diseases, as shown in knockout mice, such as skeletal defects, familial primary pulmonary hypertension and neoplasias. Osteosarcoma is the most frequent primary malignant tumor of bone. Due to their importance in bone development, BMPs, BMPRs and ActRs could also play a role in osteosarcoma growth and development. Previous data have shown that the overexpression of the BMPR-II was related to poor prognosis in malignant and metastatic bone tumors. We evaluate by reverse transcription-linked polymerase chain reaction analysis (RT-PCR) the expression pattern of BMPs, BMPRs and ActRs in five different human osteosarcoma cell lines (MG63, G292, HOS, SaOS and U2). Moreover, we performed the mutational screening of the complete BMPR-II mRNA by automated sequencing of the correspondent cDNA to evaluate the presence of point mutations in osteosarcoma cell lines. All the osteosarcoma cell lines studied simultaneously expressed the BMPs, BMPRs and ActRs investigated. No mutations were detected in the BMPR-II cDNA. Our results suggest the presence of a mechanism involving the simultaneous activation of the BMPs and their receptors in osteosarcoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11743655

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

Review 1.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  rhBMP-2 has adverse effects on human oral carcinoma cell lines in vivo.

Authors:  Natalia A Kokorina; James S Lewis; Stanislav O Zakharkin; Paul H Krebsbach; Brian Nussenbaum
Journal:  Laryngoscope       Date:  2011-10-13       Impact factor: 3.325

Review 3.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

Review 4.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

5.  ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells.

Authors:  Sarah A Maas; Nina M Donghia; Kathleen Tompkins; Oded Foreman; Kevin D Mills
Journal:  BMC Biol       Date:  2010-10-27       Impact factor: 7.431

Review 6.  Can heparins stimulate bone cancer stem cells and interfere with tumorigenesis?

Authors:  M Reza Sadaie
Journal:  Ther Adv Drug Saf       Date:  2011-12

Review 7.  Roles of bone morphogenetic protein signaling in osteosarcoma.

Authors:  Alan Nguyen; Michelle A Scott; Sarah M Dry; Aaron W James
Journal:  Int Orthop       Date:  2014-09-11       Impact factor: 3.075

Review 8.  Bone morphogenetic protein signaling in musculoskeletal cancer.

Authors:  Myrto Bami; Andreas F Mavrogenis; Andrea Angelini; Mandy Milonaki; Evanthia Mitsiokapa; Dimitrios Stamoulis; Panayotis N Soucacos
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-04       Impact factor: 4.553

9.  NELL-1 expression in tumors of cartilage.

Authors:  Jia Shen; Gregory LaChaud; Swati Shrestha; Greg Asatrian; Xinli Zhang; Sarah M Dry; Chia Soo; Kang Ting; Aaron W James
Journal:  J Orthop       Date:  2015-10-27

10.  The effect of bone morphogenetic protein-2 on osteosarcoma metastasis.

Authors:  Jonathan Gill; Patrick Connolly; Michael Roth; So Hak Chung; Wendong Zhang; Sajida Piperdi; Bang Hoang; Rui Yang; Hillary Guzik; Jonathan Morris; Richard Gorlick; David S Geller
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.